Systemic Treatment Options for Cutaneous Lupus and Dermatomyositis

Conclusions

• Thalidomide and lenalidomide can be highly effective third-line options for refractory cutaneous lupus, often producing dramatic clinical improvement after antimalarials and other standard therapies fail.
• Because thalidomide is limited by teratogenicity, peripheral neuropathy, thrombosis risk, and sedation, safe use depends on strict REMS enrollment, pregnancy prevention, and close symptom and lab monitoring.
• Lenalidomide appears to preserve the efficacy of thalidomide while reducing neuropathy risk, and dose tapering to less frequent maintenance can help maintain control while limiting toxicity.
• Anifrolumab is emerging as a major breakthrough for refractory cutaneous lupus, with rapid and substantial improvement in skin disease even in severe discoid and mucosal disease.
• The main safety signal for anifrolumab is herpes zoster and related respiratory infections, but vaccination and, when needed, antiviral prophylaxis can mitigate this risk enough to make treatment feasible.
• IVIG is an effective, non-immunosuppressive option for dermatomyositis and can be especially useful when immunosuppression is undesirable, including in complex or malignancy-associated cases.
• The most important IVIG adverse effects are headache, fever, nausea, and possible thromboembolism, but these can often be reduced by slower infusion rates, hydration, and dose-splitting.
• Available cohort data suggest IVIG does not dramatically increase venous thromboembolism risk in dermatomyositis overall, though baseline clotting risk factors still matter.
• JAK inhibition is a promising mechanistically targeted strategy in dermatomyositis because interferon signaling correlates with disease activity and blocking that pathway improves skin outcomes and pruritus.
• Lipid changes and boxed warnings for MACE, thrombosis, and malignancy require careful risk stratification and monitoring, but they do not necessarily outweigh benefit in appropriately selected dermatomyositis patients.
• Brepocitinib and other next-generation JAK/TYK2-targeting agents may further improve dermatomyositis outcomes by more directly suppressing the interferon pathway.
• Combining IVIG with JAK inhibitors appears to provide additional benefit in difficult dermatomyositis cases without producing a large additive thrombosis signal in the limited available cohort data.
• Overall, the presentation argues that with thoughtful screening, vaccination, and monitoring, clinicians can safely use newer systemic therapies to achieve major disease control in otherwise refractory cutaneous lupus and dermatomyositis.